ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas
A phase 2 trial of HS-20093 in osteosarcoma, run by Hansoh BioMedical R&D Company, now recruiting.
Overview
ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas is a phase 2 interventional study registered as NCT05830123 by Hansoh BioMedical R&D Company, with 170 participants planned, started 2023-06-08 and due to reach its primary completion in 2025-12-31. Interventions recorded: HS-20093. Conditions listed: Osteosarcoma, Sarcoma. No results are recorded here; the registry entry is the source.
Setting
ARTEMIS-002: A Phase 2, Multicenter, Open-label Study of Intravenous Administration of HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas
Phase
Phase 2
Sponsor
Hansoh BioMedical R&D Company
Registry
Enrolled
170